1. Home
  2. GUG vs CRVS Comparison

GUG vs CRVS Comparison

Compare GUG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GUG
  • CRVS
  • Stock Information
  • Founded
  • GUG 2021
  • CRVS 2014
  • Country
  • GUG United States
  • CRVS United States
  • Employees
  • GUG N/A
  • CRVS N/A
  • Industry
  • GUG Trusts Except Educational Religious and Charitable
  • CRVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GUG Finance
  • CRVS Health Care
  • Exchange
  • GUG Nasdaq
  • CRVS Nasdaq
  • Market Cap
  • GUG 470.0M
  • CRVS 305.4M
  • IPO Year
  • GUG N/A
  • CRVS 2016
  • Fundamental
  • Price
  • GUG $15.31
  • CRVS $4.17
  • Analyst Decision
  • GUG
  • CRVS Strong Buy
  • Analyst Count
  • GUG 0
  • CRVS 4
  • Target Price
  • GUG N/A
  • CRVS $15.00
  • AVG Volume (30 Days)
  • GUG 108.9K
  • CRVS 1.0M
  • Earning Date
  • GUG 01-01-0001
  • CRVS 08-05-2025
  • Dividend Yield
  • GUG 9.67%
  • CRVS N/A
  • EPS Growth
  • GUG N/A
  • CRVS N/A
  • EPS
  • GUG N/A
  • CRVS N/A
  • Revenue
  • GUG N/A
  • CRVS N/A
  • Revenue This Year
  • GUG N/A
  • CRVS N/A
  • Revenue Next Year
  • GUG N/A
  • CRVS N/A
  • P/E Ratio
  • GUG N/A
  • CRVS N/A
  • Revenue Growth
  • GUG N/A
  • CRVS N/A
  • 52 Week Low
  • GUG $12.71
  • CRVS $1.96
  • 52 Week High
  • GUG $15.06
  • CRVS $10.00
  • Technical
  • Relative Strength Index (RSI)
  • GUG 44.01
  • CRVS 53.38
  • Support Level
  • GUG $15.40
  • CRVS $4.08
  • Resistance Level
  • GUG $15.69
  • CRVS $4.31
  • Average True Range (ATR)
  • GUG 0.18
  • CRVS 0.25
  • MACD
  • GUG -0.03
  • CRVS 0.01
  • Stochastic Oscillator
  • GUG 4.69
  • CRVS 68.66

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: